AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17845737 — intervention group
Group type: EXPERIMENTAL
Intervention: Lavender aroma
Number of subjects: 96
Study 17845737 — intervention group
Group type: EXPERIMENTAL
Intervention: Instructional prime (expecting aroma to inhibit relaxation)
Number of subjects: 96
Study 17845737 — intervention group
Group type: EXPERIMENTAL
Intervention: Instructional prime (expecting aroma to facilitate relaxation)
Number of subjects: 96
Study 17845737 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported relaxation (changes in state anxiety)
Number of subjects: 96
Study 17845737 — intervention group
Group type: EXPERIMENTAL
Intervention: Attitudes towards aromatherapy
Number of subjects: 96
Study 17845737 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96
Study 17845737 — intervention group
Group type: COMPARATOR
Intervention: No aroma
Number of subjects: 96
Study 16181565 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined hydrotherapy and land-based physiotherapy
Number of subjects: 78
Study 16181565 — intervention group
Group type: COMPARATOR
Intervention: Land-based physiotherapy only
Number of subjects: 78
Study 11557899 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative radiotherapy
Number of subjects: 0
Study 11557899 — intervention group
Group type: COMPARATOR
Intervention: Total mesorectal excision without preoperative radiotherapy
Number of subjects: 0
Study 10204370 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginkgo biloba extract (EGb 761)
Number of subjects: 208
Study 10204370 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginkgo biloba extract (EGb 761) combined with components of the tricarboxylic acid cycle
Number of subjects: 208
Study 7825044 — intervention group
Group type: COMPARATOR
Intervention: Iliac autograft
Number of subjects: 144
Study 7825044 — intervention group
Group type: EXPERIMENTAL
Intervention: Demineralized cancellous chips
Number of subjects: 144
Study 7825044 — intervention group
Group type: EXPERIMENTAL
Intervention: Demineralized cortical powder
Number of subjects: 144
Study 7825044 — intervention group
Group type: EXPERIMENTAL
Intervention: Demineralized cortical powder mixed with autograft
Number of subjects: 144
Study 7825044 — intervention group
Group type: EXPERIMENTAL
Intervention: Mineralized cancellous chips
Number of subjects: 144
Study 3047581 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (0.15 mg per kilogram of body weight every six hours for four days)
Number of subjects: 200
Study 2025471 — intervention group
Group type: EXPERIMENTAL
Intervention: flumazenil 0.1-2 mg
Number of subjects: 120
Study 2025471 — intervention group
Group type: EXPERIMENTAL
Intervention: flumazenil 0.1-2 mg (for diazepam sedation)
Number of subjects: 120
Study 2025471 — intervention group
Group type: EXPERIMENTAL
Intervention: flumazenil 0.1-2 mg (for midazolam sedation)
Number of subjects: 120
Study 2025471 — intervention group
Group type: COMPARATOR
Intervention: flumazenil 0.1-2 mg and placebo
Number of subjects: 120
Study 795260 — intervention group
Group type: EXPERIMENTAL
Intervention: Fructose (F)
Number of subjects: 125
Study 795260 — intervention group
Group type: EXPERIMENTAL
Intervention: Xylitol (X)
Number of subjects: 125
Study 795260 — intervention group
Group type: COMPARATOR
Intervention: Sucrose (S)
Number of subjects: 125
Study 31791415 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention package (condom promotion, HIV and syphilis testing, reimbursement for syphilis treatment costs, and free anti-retroviral therapy)
Number of subjects: 1024
Study 31791415 — intervention group
Group type: COMPARATOR
Intervention: Current standard of care
Number of subjects: 1024
Study 28720121 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily SMS reminders of antihypertensive medication intake provided by pharmacists in addition to standard pharmaceutical care
Number of subjects: 300
Study 28720121 — intervention group
Group type: COMPARATOR
Intervention: Standard pharmaceutical care
Number of subjects: 300
Study 28720121 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily SMS reminders
Number of subjects: 300
Study 26096637 — intervention group
Group type: EXPERIMENTAL
Intervention: Perampanel (4, 8, and 12 mg)
Number of subjects: 1478
Study 26096637 — intervention group
Group type: EXPERIMENTAL
Intervention: Perampanel
Number of subjects: 1478
Study 23442091 — intervention group
Group type: EXPERIMENTAL
Intervention: Episodic future thinking task in older adults
Number of subjects: 0
Study 23442091 — intervention group
Group type: EXPERIMENTAL
Intervention: Episodic future thinking task in young adults
Number of subjects: 0
Study 21422479 — intervention group
Group type: EXPERIMENTAL
Intervention: Subantimicrobial-dose doxycycline (SDD)
Number of subjects: 128
Study 21422479 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 128
Study 19221011 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 g sucrose in water (500 ml)
Number of subjects: 7
Study 19221011 — intervention group
Group type: COMPARATOR
Intervention: 80 mg sucralose in 500 ml normal saline (0.4 mM)
Number of subjects: 7
Study 19221011 — intervention group
Group type: COMPARATOR
Intervention: 800 mg sucralose in 500 ml normal saline (4 mM)
Number of subjects: 7
Study 19221011 — intervention group
Group type: COMPARATOR
Intervention: 500 ml normal saline
Number of subjects: 7
Study 18218205 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure-Controlled Ventilation (PCV)
Number of subjects: 23
Study 18218205 — intervention group
Group type: EXPERIMENTAL
Intervention: Volume-Controlled Ventilation (VCV)
Number of subjects: 23
Study 15166004 — intervention group
Group type: EXPERIMENTAL
Intervention: C12 (lauric acid)
Number of subjects: 8
Study 15166004 — intervention group
Group type: EXPERIMENTAL
Intervention: C10 (decanolic acid)
Number of subjects: 8
Study 15166004 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 8
Study 11286849 — intervention group
Group type: EXPERIMENTAL
Intervention: 68 Gy
Number of subjects: 225
Study 11286849 — intervention group
Group type: EXPERIMENTAL
Intervention: 78 Gy
Number of subjects: 225
Study 11286849 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerator A (used for treatment)
Number of subjects: 225
Study 11286849 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerator B (used for treatment)
Number of subjects: 225
Study 9885079 — intervention group
Group type: EXPERIMENTAL
Intervention: Complex maze
Number of subjects: 20
Study 9885079 — intervention group
Group type: COMPARATOR
Intervention: Simple maze
Number of subjects: 20
Study 7993937 — intervention group
Group type: EXPERIMENTAL
Intervention: GM-CSF primed-PBPC
Number of subjects: 23
Study 2729180 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose metoclopramide (2 mg/kg X 4)
Number of subjects: 34
Study 2729180 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide plus high-dose methylprednisolone (250 mg X 2)
Number of subjects: 34
Study 29649914 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive affect skills intervention
Number of subjects: 159
Study 29649914 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 159
Study 30974969 — intervention group
Group type: EXPERIMENTAL
Intervention: Particle-depleted diesel exhaust (PDDE) plus allergen
Number of subjects: 14
Study 30974969 — intervention group
Group type: EXPERIMENTAL
Intervention: Diesel exhaust (DE) plus allergen
Number of subjects: 14
Study 30974969 — intervention group
Group type: COMPARATOR
Intervention: Filtered air
Number of subjects: 14
Study 30974969 — intervention group
Group type: EXPERIMENTAL
Intervention: Particle-depleted diesel exhaust (PDDE)
Number of subjects: 14
Study 30974969 — intervention group
Group type: EXPERIMENTAL
Intervention: Diesel exhaust (DE)
Number of subjects: 14
Study 26122046 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung-protective ventilation (low tidal volume, positive end-expiratory pressure, recruitment maneuvers)
Number of subjects: 95
Study 26122046 — intervention group
Group type: COMPARATOR
Intervention: Non-protective ventilation (high tidal volume, zero end-expiratory pressure)
Number of subjects: 95
Study 23537420 — intervention group
Group type: EXPERIMENTAL
Intervention: Nocturnal continuous glucose monitoring (CGM)
Number of subjects: 72
Study 21528597 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture and moxibustion group
Number of subjects: 100
Study 21528597 — intervention group
Group type: COMPARATOR
Intervention: Acupuncture group
Number of subjects: 100
Study 19041352 — intervention group
Group type: EXPERIMENTAL
Intervention: Tdap3v
Number of subjects: 2284
Study 19041352 — intervention group
Group type: COMPARATOR
Intervention: Tdap5v
Number of subjects: 2284
Study 16750448 — intervention group
Group type: EXPERIMENTAL
Intervention: travoprost 0.004%
Number of subjects: 110
Study 16750448 — intervention group
Group type: COMPARATOR
Intervention: latanoprost 0.005%/timolol 0.5%
Number of subjects: 110
Study 15336988 — intervention group
Group type: EXPERIMENTAL
Intervention: Bicaval orthotopic heart transplantation with DeVega tricuspid valve annuloplasty
Number of subjects: 60
Study 15336988 — intervention group
Group type: COMPARATOR
Intervention: Bicaval orthotopic heart transplantation
Number of subjects: 60
Study 11339688 — intervention group
Group type: EXPERIMENTAL
Intervention: Salt-sensitive individuals (n = 16)
Number of subjects: 43
Study 11339688 — intervention group
Group type: COMPARATOR
Intervention: Salt-resistant individuals (n = 27)
Number of subjects: 43
Study 9470834 — intervention group
Group type: EXPERIMENTAL
Intervention: CVI 5‐FU at a dose of 750 mg/m2/day, 7 d every 21 d (n = 77)
Number of subjects: 155
Study 9470834 — intervention group
Group type: COMPARATOR
Intervention: Bolus 5‐FU 500 mg/m2/d x 5 d every 28 d (n = 78)
Number of subjects: 155
Study 7943788 — intervention group
Group type: EXPERIMENTAL
Intervention: Succinylcholine 100 micrograms/kg
Number of subjects: 40
Study 7943788 — intervention group
Group type: EXPERIMENTAL
Intervention: Succinylcholine 175 micrograms/kg
Number of subjects: 40
Study 7943788 — intervention group
Group type: EXPERIMENTAL
Intervention: Succinylcholine 250 micrograms/kg
Number of subjects: 40
Study 7943788 — intervention group
Group type: EXPERIMENTAL
Intervention: Succinylcholine 375 micrograms/kg
Number of subjects: 40
Study 7943788 — intervention group
Group type: EXPERIMENTAL
Intervention: Succinylcholine
Number of subjects: 40
Study 3370065 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 mg torasemide once daily
Number of subjects: 87
Study 3370065 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg torasemide once daily
Number of subjects: 87
Study 3370065 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher dosages of torasemide for non-responders
Number of subjects: 87
Study 3370065 — intervention group
Group type: EXPERIMENTAL
Intervention: Torasemide treatment
Number of subjects: 87
Study 30328307 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided tissue regeneration (GTR) using grafts and collagen membranes
Number of subjects: 25
Study 26847813 — intervention group
Group type: EXPERIMENTAL
Intervention: Temozolomide plus Bevacizumab (TMZ + BEV)
Number of subjects: 102
Study 26847813 — intervention group
Group type: COMPARATOR
Intervention: Temozolomide (TMZ)
Number of subjects: 102
Study 23795708 — intervention group
Group type: EXPERIMENTAL
Intervention: More numerate adults making decisions among a small number of alternatives (2 to 16 plans)
Number of subjects: 0
Study 23795708 — intervention group
Group type: COMPARATOR
Intervention: Less numerate adults making decisions among a small number of alternatives (2 to 16 plans)
Number of subjects: 0
Study 23795708 — intervention group
Group type: EXPERIMENTAL
Intervention: Numeracy as a moderator
Number of subjects: 0
Study 21093231 — intervention group
Group type: EXPERIMENTAL
Intervention: Olive oil meal (22% SFA, 38% MUFA, 4% PUFA)
Number of subjects: 21
Study 21093231 — intervention group
Group type: EXPERIMENTAL
Intervention: Butter meal (35% SFA, 22% MUFA, 4% PUFA)
Number of subjects: 21
Study 21093231 — intervention group
Group type: EXPERIMENTAL
Intervention: Walnuts meal (20% SFA, 24% MUFA, 16% PUFA, 4% α-linolenic acid)
Number of subjects: 21
Study 21093231 — intervention group
Group type: COMPARATOR
Intervention: Control group (Olive oil meal)
Number of subjects: 21
Study 19768454 — intervention group
Group type: COMPARATOR
Intervention: Bupivicaine 0.5% (20 ml)
Number of subjects: 60
Study 19768454 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivicaine 0.5% (20 ml) with 10 mg morphine
Number of subjects: 60
Study 18333861 — intervention group
Group type: EXPERIMENTAL
Intervention: Maraviroc (3-1200 mg)
Number of subjects: 0
Study 18333861 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 16003291 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil (240 mg daily for 6 days)
Number of subjects: 12
Study 16003291 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 16003291 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 12
Study 12479993 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapist-administered group training (TG)
Number of subjects: 77
Study 12479993 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-help format (SH)
Number of subjects: 77
Study 12479993 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control group (WC)
Number of subjects: 77
Study 10065784 — intervention group
Group type: EXPERIMENTAL
Intervention: IVF (group 1)
Number of subjects: 96
Study 10065784 — intervention group
Group type: COMPARATOR
Intervention: Standard infertility treatment algorithm (group 2)
Number of subjects: 96
Study 7752008 — intervention group
Group type: EXPERIMENTAL
Intervention: Preterm infant formula with higher concentrations of zinc, copper, calcium, magnesium, and potassium until 2 months past expected term
Number of subjects: 33
Study 7752008 — intervention group
Group type: COMPARATOR
Intervention: Term infant formula
Number of subjects: 33
Study 2257872 — intervention group
Group type: EXPERIMENTAL
Intervention: Rythmodan (conventionally formulated disopyramide) 150 mg
Number of subjects: 8
Study 2257872 — intervention group
Group type: EXPERIMENTAL
Intervention: Rythmodan 250 mg
Number of subjects: 8
Study 2257872 — intervention group
Group type: EXPERIMENTAL
Intervention: Rythmodan Retard (controlled‐release disopyramide) 250 mg
Number of subjects: 8
Study 2257872 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 496440 — intervention group
Group type: EXPERIMENTAL
Intervention: Ectocervical scraping and endocervical curettage
Number of subjects: 558
Study 496440 — intervention group
Group type: COMPARATOR
Intervention: Cone biopsy
Number of subjects: 558
Study 496440 — intervention group
Group type: COMPARATOR
Intervention: Primary hysterectomy
Number of subjects: 558
Study 30962231 — intervention group
Group type: EXPERIMENTAL
Intervention: Goal-directed financial incentives for weight loss (up to $750 over 6 months for participating in an intensive weight management programme, self-monitoring weight and diet, and meeting physical activity guidelines)
Number of subjects: 795
Study 30962231 — intervention group
Group type: EXPERIMENTAL
Intervention: Outcome-based financial incentives for weight loss (up to $750 over 6 months for achieving a ≥1.5% to ≥5% reduction in baseline weight)
Number of subjects: 795
Study 30962231 — intervention group
Group type: COMPARATOR
Intervention: Provision of health behaviour change resources alone (1-year commercial weight loss programme membership, self-monitoring tools, health education, and monthly check-ins)
Number of subjects: 795
Study 27100913 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine sedation (IV bolus of 1 mcg/kg over 10 min followed by maintenance infusion of 0.5 mcg/kg/h)
Number of subjects: 76
Study 27100913 — intervention group
Group type: COMPARATOR
Intervention: General Anesthesia (GA) with endotracheal intubation and balanced anesthesia
Number of subjects: 76
Study 25773594 — intervention group
Group type: EXPERIMENTAL
Intervention: Dipyridamole
Number of subjects: 94
Study 25773594 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 94
Study 25439713 — intervention group
Group type: EXPERIMENTAL
Intervention: Schroth exercises combined with standard care for 6 months
Number of subjects: 258
Study 25439713 — intervention group
Group type: COMPARATOR
Intervention: Standard care (observation or bracing)
Number of subjects: 258
Study 25439713 — intervention group
Group type: EXPERIMENTAL
Intervention: Schroth exercises
Number of subjects: 258
Study 25439713 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 258
Study 22765352 — intervention group
Group type: EXPERIMENTAL
Intervention: Action observation treatment (observing video clips showing daily age-appropriate actions and imitating them)
Number of subjects: 15
Study 22765352 — intervention group
Group type: COMPARATOR
Intervention: Control group (observing video clips with no motor content and executing the same actions as cases)
Number of subjects: 15
Study 18812416 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibration therapy (VT)
Number of subjects: 29
Study 19015065 — intervention group
Group type: EXPERIMENTAL
Intervention: Various therapeutic approaches including surgery, radiotherapy, and chemotherapy
Number of subjects: 0
Study 15644821 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.37 mg/kg/week
Number of subjects: 50
Study 15644821 — intervention group
Group type: COMPARATOR
Intervention: 0.24 mg/kg/week
Number of subjects: 50
Study 15644821 — intervention group
Group type: COMPARATOR
Intervention: 0.24‐‐>0.37 mg/kg/week
Number of subjects: 50
Study 12891162 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based compliance monitoring device plus usual care
Number of subjects: 18
Study 12891162 — intervention group
Group type: COMPARATOR
Intervention: Usual care only (Control)
Number of subjects: 18
Study 10481520 — intervention group
Group type: EXPERIMENTAL
Intervention: Metacholine provocation in asthmatics
Number of subjects: 27
Study 10481520 — intervention group
Group type: COMPARATOR
Intervention: Asymptomatic period in asthmatics
Number of subjects: 27
Study 8570130 — intervention group
Group type: EXPERIMENTAL
Intervention: RT plus MLT (20 mg/daily orally)
Number of subjects: 30
Study 8570130 — intervention group
Group type: COMPARATOR
Intervention: RT alone (60 Gy)
Number of subjects: 30
Study 8570130 — intervention group
Group type: EXPERIMENTAL
Intervention: RT plus MLT
Number of subjects: 30
Study 1279821 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatostatin (250 micrograms per hour continuous intravenous infusion for three days)
Number of subjects: 63
Study 1279821 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study 4022350 — intervention group
Group type: EXPERIMENTAL
Intervention: Azathioprine (2 mg/kg) with prednisone
Number of subjects: 27
Study 4022350 — intervention group
Group type: COMPARATOR
Intervention: Prednisone alone
Number of subjects: 27
Study 31618129 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab plus chemotherapy (BC)
Number of subjects: 403
Study 31618129 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 403
Study 29688582 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral esaxerenone (5-200 mg single-dose; 10-100 mg multiple-dose over 10 days)
Number of subjects: 88
Study 29688582 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral esaxerenone (single-dose)
Number of subjects: 88
Study 29688582 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral esaxerenone (multiple-dose)
Number of subjects: 88
Study 29688582 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88
Study 27003763 — intervention group
Group type: EXPERIMENTAL
Intervention: L-arginine
Number of subjects: 100
Study 27003763 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 24212326 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-tailored advice
Number of subjects: 0
Study 24212326 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-component intervention
Number of subjects: 0
Study 24212326 — intervention group
Group type: EXPERIMENTAL
Intervention: Free fruit initiative
Number of subjects: 0
Study 24212326 — intervention group
Group type: EXPERIMENTAL
Intervention: Free healthy breakfast
Number of subjects: 0
Study 24817035 — intervention group
Group type: EXPERIMENTAL
Intervention: JNJ 39758979 (600 mg)
Number of subjects: 24
Study 24817035 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetirizine (10 mg)
Number of subjects: 24
Study 24817035 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 22448783 — intervention group
Group type: EXPERIMENTAL
Intervention: Lu AA21004 (75 mg single dosing, 60 mg multiple dosing)
Number of subjects: 97
Study 22448783 — intervention group
Group type: EXPERIMENTAL
Intervention: Lu AA34443 (major metabolite)
Number of subjects: 97
Study 19485963 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous feedback of outcome to patients and clinicians
Number of subjects: 294
Study 17689896 — intervention group
Group type: EXPERIMENTAL
Intervention: Chinese herbal medicines (CHM)
Number of subjects: 31
Study 17689896 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone replacement therapy (HRT)
Number of subjects: 31
Study 17689896 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 15059637 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidants (AO) - 1000 mg vitamin C and 400 IU RRR-alpha-tocopheryl acetate
Number of subjects: 21
Study 15059637 — intervention group
Group type: COMPARATOR
Intervention: Placebos (PL)
Number of subjects: 21
Study 15059637 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidants (AO)
Number of subjects: 21
Study 15059637 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance exercise
Number of subjects: 21
Study 11584934 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination regimen (pentamidine 2 mg/kg IM on alternate days + allopurinol 15 mg/kg in three divided doses for 30 days)
Number of subjects: 158
Study 11584934 — intervention group
Group type: COMPARATOR
Intervention: Single regimen (pentamidine 4 mg/kg IM on alternate days for 15 injections in 30 days)
Number of subjects: 158
Study 9617976 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine 60 mg
Number of subjects: 0
Study 9617976 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine 20 mg
Number of subjects: 0
Study 9617976 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 0
Study 9617976 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 8543488 — intervention group
Group type: EXPERIMENTAL
Intervention: Meropenem
Number of subjects: 173
Study 8543488 — intervention group
Group type: COMPARATOR
Intervention: Imipenem/cilastatin
Number of subjects: 173
Study 1782768 — intervention group
Group type: EXPERIMENTAL
Intervention: Eugenol
Number of subjects: 0